Author

T. Kuilman

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Approach:deep learning· 1 Research Focus:differential expression· 1 Research Focus:gene regulatory network inference· 1 Organism:human· 1 Approach:statistical model· 1

Frequent Co-Authors

A. Shahrabi· 1 shared B. de Bruijn· 1 shared C. U. Blank· 1 shared D. J. Adams· 1 shared D. S. Peeper· 1 shared D. W. Vredevoogd· 1 shared E. A. Rozeman· 1 shared J. Boshuizen· 1 shared

Activity by Year

2020-2020 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Shahrabi

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

PREDICTIVE IMMUNE CHECKPOINT BLOCKADE CLASSIFIERS DISTINGUISHING MONO- VERSUS COMBINATION THERAPY REQUIREMENT

O. Krijgsman, K. Kemper, J. Boshuizen, D. W. Vredevoogd, E. A. Rozeman, S. Ibanez Molero, B. de Bruijn, P. Cornelissen-Steijger, A. Shahrabi, M. Del Castillo Velasco-Herrera, J.-Y. Song, M. A. Ligtenberg, R. J. C. Kluin, T. Kuilman, P. Ross-MacDonald, , D. S. Peeper

This paper develops two genetic signatures, InTumor and ExTumor, to predict immune checkpoint blockade response in melanoma patients, enabling stratification for monotherapy or combination therapy.

bioRxiv · Jul 14, 2020 · PreprintCancer Biology